Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 4, 2004, Pages 935-942

  Lonergan, J Tyler ^a   McComsey, Grace A ^b   Fisher, Robin L ^c   Shalit, Peter ^d   File Jr , Thomas M ^e   Ward, Douglas J ^f   Williams, Vanessa C ^c   Hessenthaler, Siegrid M ^c   Lindsey, Laura ^c   Hernandez, Jaime E ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

^d SWEDISH MEDICAL CENTER   (United States)

^e SUMMA HEALTH SYSTEM   (United States)

^f Dupont Circle Physicians Group   (United States)

Author keywords

Abacavir; Combivir; HIV infection; Hyperlactatemia; Lipoatrophy; Stavudine; Zidovudine

Indexed keywords

ABACAVIR; AMINOTRANSFERASE; LACTIC ACID; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; MULTICENTER STUDY; NAUSEA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LACTATES; MALE; MIDDLE AGED; RECURRENCE; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 3242708621     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200408010-00007     Document Type: Article

References (24)

1. Hurst M, Noble S. Stavudine. An update of its use in the treatment of HIV infection. Drugs. 1999;58:919-949.
2. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis. 2001;33:1931-1937.
3. Harris M, Chan KJ, Tesiorowski AA, et al. Random venous lactate levels among HIV-positive patients on antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:448-450.
4. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis. 2002;15:23-29.
5. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 2001;15:717-723.
6. Vrouenraets SME, Treskes M, Regez RM, et al. Hyperlactatemia in HIV-infected patients: the role of NRTI treatment. Antivir Ther. 2002;7:239-244.
7. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 2002;16:1341-1349.
8. Leclercq P, Derradji M, Colombe B, et al. Lactate endogenous production is a good tool to evaluate mitochondrial dysfunction [abstract]. Presented at the Third International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Infection, Athens, October 2001.
9. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000;22:685-708.
10. Gerard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS. 2000;14:2723-2730.
11. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis. 2000;31:162-166.
12. Lonergan JT, Havlir D, Barber R, et al. Incidence of symptomatic hyperlactatemia in HIV-infected adults [abstract 35]. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, February 2002.
13. Cornejo-Juarez P, Sierra-Madero J, Volkow-Fernandez P. Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment. Arch Med Res. 2003;34:64-69.
14. Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1945;1:80-83.
15. Antoniou T, Weisdorf T, Gough K. Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion. CMAJ. 2003;168:195-198.
16. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy - a randomized trial. JAMA. 2002;288:207-215.
17. Lonergan JT, Barber E, Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS. 2003;17:2495-2499.
18. Kumar PN. Prospective study of hyperlipidemia in ART-naïve subjects taking Combivir/abacavir (COM/ABC) vs. Combivir/nelfinavir (COM/NFV) vs. stavudine/lamivudine/nelfinavir (d4T/3TC/NFV): 48-week data [abstract 33]. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, February 2002.
19. Sundar K, Suarez M, Banogon PE, et al. Zidovudine induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med. 1997;25:1425-1430.
20. Brinkman K. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis. 2000;31:167-169.
21. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS. 2001;15:795-797.
22. White A, John M, Moore C, et al. Raised lactate levels are common and may be predictive of subcutaneous fat wasting [poster P82]. Presented at the Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, September 2000.
23. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263-270.
24. Carr A, Miller J, Eisman JA, et al. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight preantiretroviral therapy. AIDS. 2001;15:703-709.